Premium
Infusion of Human and Canine Factor VIII in Dogs with von Willebrand's Disease: Studies of the von Willebrand and Factor VIII Synthesis Stimulating Factors
Author(s) -
BOUMA B. N.,
DODDS W. JEAN,
MOURIK J. A.,
SIXMA J. J.,
WEBSTER W. P.
Publication year - 1976
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1976.tb01184.x
Subject(s) - von willebrand factor , platelet , chemistry , ristocetin , endocrinology , medicine , von willebrand disease , antigen , factor ix , bleeding time , saline , factor x , immunology , platelet aggregation , thrombin
Dogs with von Willebrand's disease (VWD) were infused with a highly purified human and canine factor VIII preparation. Control infusions were performed using isotonic saline solution. Following all of the concentrate infusions, the bleeding times were shortened to within the normal range for up to 4 h. Factor VIII activity rose immediately after infusion, rapidly returned to preinfusion levels, and then increased again at 18 h. The levels of factor VIII‐related antigen (F VIII‐RA) as measured with anticanine factor VIII also increased after infusion and then gradually declined. There was no further increase in F VIII‐RA at 18 h, when the factor VIII activity showed the secondary increase characteristic of VWD. With antihuman factor VIII, two identifiable antigens were present in the plasma of the dogs given human factor VIII. The reduced platelet retention of these animals was not significantly altered following infusion, whereas ristocetin‐induced platelet aggregation was corrected in one of the dogs given human factor VIII. These studies indicate that factor VIII procoagulant and von Willebrand factor activities reside on a single molecule or form part of a molecular complex. In addition, the factor VIII preparations appeared to contain the factor VIII synthesis‐stimulating factor and/or a precursor of factor VIII procoagulant activity.